Holen Sie sich die Stockscreener-App
1.23
3.36%
0.04
Handel nachbörslich:
1.23
Schlusskurs vom Vortag:
$1.19
Offen:
$1.2
24-Stunden-Volumen:
396.13K
Relative Volume:
0.53
Marktkapitalisierung:
$39.82M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.00M
KGV:
-0.4424
EPS:
-2.78
Netto-Cashflow:
$-55.26M
1W Leistung:
-0.81%
1M Leistung:
+17.14%
6M Leistung:
-79.57%
1J Leistung:
-79.01%
1-Tages-Spanne:
$1.15
$1.27
1-Wochen-Bereich:
$1.15
$1.3395
52-Wochen-Spanne:
$1.05
$10.16
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Firmenname
Acrivon Therapeutics Inc
Sektor
Branche
Telefon
617-207-8979
Adresse
480 ARSENAL WAY, SUITE 100, WATERTOWN
Vergleichen Sie ACRV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.23 | 39.82M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-05 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-31 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-12-15 | Fortgesetzt | Jefferies | Buy |
| 2023-10-05 | Eingeleitet | Maxim Group | Buy |
| 2023-06-02 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-04-27 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2023-04-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-12-12 | Eingeleitet | Jefferies | Buy |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Acrivon Therapeutics Inc Aktie (ACRV) Neueste Nachrichten
Acrivon Therapeutics Holds Annual Stockholders Meeting - TipRanks
Analysts Offer Predictions for ACRV FY2026 Earnings - Defense World
Long Term Trading Analysis for (ACRV) - news.stocktradersdaily.com
Nuveen Asset Management LLC Sells 12,377 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Northern Trust Corp Has $706,000 Stock Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of “Buy” from Analysts - Defense World
Acrivon Therapeutics: Promising Clinical Developments and Strategic Focus Support Buy Rating - TipRanks
FY2025 EPS Estimate for Acrivon Therapeutics Cut by Analyst - Defense World
Q3 EPS Forecast for Acrivon Therapeutics Boosted by Analyst - Defense World
(ACRV) Investment Analysis and Advice - news.stocktradersdaily.com
Jones Trading Reaffirms Hold Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics (ACRV) Downgraded by Jones Trading | ACRV S - GuruFocus
Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch - Yahoo Finance
Oppenheimer Issues Pessimistic Forecast for Acrivon Therapeutics (NASDAQ:ACRV) Stock Price - Defense World
JonesResearch Downgrades Acrivon Therapeutics (ACRV) to Hold | ACRV Stock News - GuruFocus
Cantor Fitzgerald maintains Overweight on Acrivon Therapeutics stock By Investing.com - Investing.com South Africa
Acrivon Therapeutics (ACRV) Price Target Lowered by Oppenheimer - GuruFocus
Acrivon Therapeutics (ACRV) Price Target Lowered by Oppenheimer | ACRV Stock News - GuruFocus
Acrivon (ACRV) Advances Clinical Pipeline with Promising Data an - GuruFocus
Oppenheimer Cuts Price Target on Acrivon Therapeutics to $9 From $10, Keeps Outperform Rating - marketscreener.com
Acrivon Therapeutics, Inc.: Promising Clinical Data and Strategic Advancements Justify Buy Rating - TipRanks
Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewswire
Cantor Fitzgerald maintains Overweight on Acrivon Therapeutics stock - Investing.com
Acrivon Therapeutics (ACRV) Projects Funding Through Mid-2027 | - GuruFocus
Acrivon Therapeutics (ACRV) Price Target Reduced by Oppenheimer - GuruFocus
Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer - TipRanks
Acrivon Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Acrivon Therapeutics (ACRV) Price Target Reduced by Oppenheimer | ACRV Stock News - GuruFocus
Acrivon Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Acrivon Therapeutics Reports Positive ACR-368 Data for Endometrial Cancer and Appoints New Chief Medical Officer - Nasdaq
Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Resistant Endometrial Cancer Patients - Stock Titan
Acrivon Therapeutics (ACRV) to Release Earnings on Tuesday - Defense World
(ACRV) Investment Analysis - news.stocktradersdaily.com
Acrivon Therapeutics (NASDAQ:ACRV) Coverage Initiated by Analysts at Piper Sandler - Defense World
Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research
Piper Sandler Initiates Coverage on Acrivon Therapeutics (ACRV) with Overweight Rating | ACRV Stock News - GuruFocus
Piper Sandler sets $6 target for Acrivon stock, rates it Overweight - Investing.com Nigeria
Piper Sandler sets $6 target for Acrivon stock, rates it Overweight By Investing.com - Investing.com South Africa
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Shares Sold by JPMorgan Chase & Co. - Defense World
Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) PT at $21.80 - Defense World
Cantor Fitzgerald Has Positive View of ACRV FY2025 Earnings - Defense World
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Decreases By 19.9% - Defense World
Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million By Investing.com - Investing.com Canada
Major Shareholder Sells Massive Stake in Acrivon Therapeutics! - TipRanks
Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million - Investing.com
Finanzdaten der Acrivon Therapeutics Inc-Aktie (ACRV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Acrivon Therapeutics Inc-Aktie (ACRV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10% Owner |
May 01 '25 |
Sale |
1.34 |
298,886 |
400,507 |
3,104,139 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 25 '25 |
Sale |
1.95 |
1,054,669 |
2,056,605 |
4,306,189 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 29 '25 |
Sale |
1.41 |
250,000 |
352,500 |
3,840,906 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 28 '25 |
Sale |
1.56 |
215,283 |
335,841 |
4,090,906 |
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):